Successful partnership continues as bispecific antibody candidate moves to GMP manufacturing; project highlights Japan's advanced capabilities in ...

NN4101, a first-in-class, connects a fully human anti-c-Kit monoclonal antibody with a vascular endothelial growth factor (VEGF) trap.

Opinions expressed by Digital Journal contributors are their own. Bringing a new biologic drug from concept to clinic is a complex journey fraught with technical and regulatory hurdles. For ...

As trade policy, regulatory scrutiny, and capital discipline reshape biologics development, sponsors are rethinking where and ...

WILMINGTON, Del., March 12, 2026 /PRNewswire/ -- Earendil Labs, a global leader in AI-driven research and development of next-generation biologics therapeutics, and WuXi Biologics (2269.HK), a global ...

The growing complexity of the field reinforces the need for standards ensuring product quality, consistency, and patient ...

Potency assay development uses DoE and QbD to improve accuracy, consistency, and regulatory readiness in biologics testing.

Company is among the first in China's drug-device combination products sector to obtain this certification, delivering superior solutions to global clients Zero non-conformities demonstrates company's ...

With each new year comes a new set of accompanying challenges, from tackling the latest innovations to new incarnations of old issues. 2025 will be no exception to this rule, and with its arrival we ...

WuXi Biologics, a leading global contract research, development and manufacturing organization, announced that it has successfully achieved ISO 13485:2016 Medical Device Quality Management System ...

Novelty Nobility expands manufacturing pact with AGC Biologics to further develop bispecific drug candidate: Chiba, Japan Tuesday, May 5, 2026, 18:00 Hrs [IST] Novelty Nobility, a ...